DXR — DAXOR CORP SEC Filings

Insider Activity

◆ Cluster Buy · 2 insiders

In the 90 days to Mar 31, 2026: 2 insiders bought $10K.

Date	Insider	Action	Shares	Price	Value
Mar 31, 2026	Michel Robert JChief Financial Officer	Buy	1,000	$9.90	$10K
Mar 20, 2026	Jefferies JohnChief Medical Officer	Buy	2,285	$0.00	$0
Mar 20, 2026	Jefferies JohnChief Medical Officer	Buy	3,656	$0.00	$0
Dec 9, 2025	Michel Robert JChief Financial Officer	Buy	3,000	$0.00	$0
Dec 9, 2025	Feldschuh Jonathan AdamChief Scientific Officer	Buy	18,000	$0.00	$0
Nov 12, 2025	Jefferies JohnChief Medical Officer	Buy	2,344	$0.00	$0

Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.

What Changed

Risk factors · Mar 29, 2011 → Mar 28, 2012

10 added · 28 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.

Newly disclosed

Although it is possible that increased coverage could lead to greater access to our products and services if the reimbursement rate is lower, this would limit the benefit to Daxor and could have a negative effect on our operating results and our business. 25 Available for Sale Securities At December 31, 2011, 81.3% of the fair market value of the Company’s investment portfolio consisted of utility stocks whose market price can be sensitive to rising interest rates.
Patents Our patents for the BVA 100 expired in 2010.The Company filed two additional patent applications for an automated instrument to measure human blood volume in March of 2012.
These applications supplement the patent application filed in the fourth quarter of 2011 for a Total Body Albumin Analyzer.
At December 31, 2010, 80.9% of the Company’s investment portfolio consisted of utility stocks.
At December 31, 2011, the Company’s investment portfolio consisted of 87 separate stocks.
This legislation was signed into law by President Obama on March 23, 2010.
The Board of Directors has authorized this minimum to be temporarily lowered to 70% when management deems it to be necessary.
The filings describe innovations which will be incorporated into the Company’s BVA-100 Blood Volume Analyzer.
House of Representatives passed The “Patient Protection and Affordable Care Act (H.R.3590).”
The Company does not know when, or if these patent applications will be approved.

No longer disclosed

The Company disclosed in its Form 10-Q for September 30, 2010 that the SEC instituted administrative proceedings pursuant to the Investment Company Act of 1940 on September 17, 2010.
In November 2009, the staff of the Northeast Regional Office of the SEC contacted the Company and invited both the Company and Dr.
Joseph Feldschuh, its President and Chief Executive Officer, respectively, received Wells Notices from the Securities and Exchange Commission (“SEC”) requesting their comments on the SEC Staff’s view that the Company was in violation of Section 7(a) of the Investment Company Act in that it was operating as an unregistered investment company.
The Company feels strongly that the extensive documentation of its history of operations presented at the administrative proceeding will demonstrate that it is primarily an operating medical instrumentation and biotechnology company and not primarily an investment company The Administrative Law Judge is required to issue an opinion no later than 300 days from September 17, 2010 pursuant to Rule 360 (a) (2) of the Commission’s Rules of Practice.
The Board of Directors has authorized this minimum to be temporarily lowered to 70% when management deems it to be necessary. 23 At December 31, 2010, the Company’s investment portfolio consisted of 68 separate stocks.
Available for Sale Securities At December 31, 2010, 80.9% of the fair market value of the Company’s investment portfolio consisted of utility stocks whose market price can be sensitive to rising interest rates.
The New York City staff of the Enforcement Division of the SEC is claiming that Daxor is primarily an investment company and not primarily an operating company.
House of Representatives passed The “Patient Protection and Affordable Care Act (H.R.3590).” This legislation was signed into law by President Obama on March 23, 2010.
However, one requirement of being an RIC is that Daxor would have to distribute at least 90% of its investment company taxable income and 90% of its net tax-exempt income to its shareholders annually.

DAXOR CORP

Similar companies

Insider Activity

What Changed